

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

**VOLUNTARY ANNOUNCEMENT – POSITIVE TOP-LINE RESULTS
FROM NVK002 TWO-YEAR PHASE III CLINICAL TRIAL
(CHINA CHAMP) IN CHINA FOR THE TREATMENT OF MYOPIA
PROGRESSION IN CHILDREN**

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) on a voluntary basis.

The Board of the Company is pleased to announce the top-line results from its two-year Phase III clinical trial (“**China CHAMP**”) of one of the Company’s core products, NVK002. Analysis of the study, after two years of treatment, demonstrated statistically significant differences in the primary efficacy endpoints between the NVK002 groups (both 0.01% and 0.02% doses) and the placebo group, with the NVK002 groups performing better than the placebo group, and indicating a dose-dependent effect. NVK002 at both doses demonstrated strong safety and high patient compliance.

China CHAMP is a randomized, double-blind, placebo-controlled, multicenter, Phase III clinical study. Its main objective is to evaluate the efficacy and safety of NVK002 (low dose atropine 0.01% and 0.02%) in the treatment of myopia progression in children and adolescents in the Chinese population. This trial involved 18 centers and enrolled 777 patients.

ABOUT NVK002

NVK002 is an investigational novel topical ophthalmic solution to control myopia progression in children and adolescents. NVK002 has a proprietary formulation that successfully addresses the instability of low-concentration atropine, this technology has intellectual property protection globally. It is preservative-free with an expected shelf life of over 24 months. According to information from China Insights Consultancy (“**CIC**”), NVK002 is currently one of the most advanced atropine drug candidates globally for treating myopia progression, and targets the broadest patient group, covering children and adolescents from 3 to 17 years old.

The clinical development of NVK002 involves two different concentrations of atropine to allow flexibility in achieving maximal efficacy and minimal adverse effects for tailoring to the needs of individual patients.

ABOUT MYOPIA PROGRESSION CONTROL

Myopia has become a major social issue that plagues the growth of children and adolescents in China. In the “14th Five-Year National Health Plan” issued by the State Council of the Chinese government, clear instructions have been made for the prevention and treatment of myopia in children and adolescents, and reduction of the overall myopia rate among children and adolescents nationwide by more than 0.5% per year. The Ministry of Education also issued the “Proposal for Parents of Comprehensive Prevention and Control of Myopia in Children and Adolescents”, calling on parents to pay attention to their children’s eye health.

According to the World Health Organization and CIC, currently there are approximately 700 million myopia patients in China, among them, 163 million are children and adolescents, who may be able to benefit from NVK002. The Board believes the potential commercialization of NVK002 will allow the Company to establish a leading position in meeting these huge unmet needs in China.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize NVK002 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, October 23, 2024

As at the date of this announcement, the Board comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors, Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors, and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.